J M Nabholtz
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
Thürlimann B, Robertson J, Nabholtz J, Buzdar A, Bonneterre J, Arimidex Study Group. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. European journal of cancer (Oxford, England : 1990) 2003; 39:2310-7.
Nov 1, 2003Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
Nov 1, 2003European journal of cancer (Oxford, England : 1990) 2003; 39:2310-7
Thürlimann Beat, Robertson J F R, Nabholtz J M, Buzdar A, Bonneterre J, Arimidex Study Group
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results
Nabholtz J, Bonneterre J, Buzdar A, Robertson J, Thürlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. European journal of cancer (Oxford, England : 1990) 2003; 39:1684-9.
Aug 1, 2003Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results
Aug 1, 2003European journal of cancer (Oxford, England : 1990) 2003; 39:1684-9
Nabholtz J M, Bonneterre J, Buzdar A, Robertson J F R, Thürlimann Beat
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
Bonneterre J, Arimidex Writing Committee, Steinberg M, Webster A, Sahmoud T, von Euler M, Thürlimann B, Robertson J, Nabholtz J, Buzdar A, Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92:2247-58.
Nov 1, 2001Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
Nov 1, 2001Cancer 2001; 92:2247-58
Bonneterre J, Arimidex Writing Committee, Steinberg M, Webster A, Sahmoud T, von Euler M, Thürlimann Beat, Robertson J F, Nabholtz J M, Buzdar A, Investigators Committee Members
Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer
Nabholtz J, Murawsky M, Alaki M, Aapro M, Drbal J, Trillet-Lenoir V, Rosso R, Rapoport B, Vandenberg T, Douma J, Deschênes L, Melnychuk D, Bezwoda W, Thürlimann B, Riva A. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. Oncology (Williston Park, N.Y.) 1997; 11:25-30.
Aug 1, 1997Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer
Aug 1, 1997Oncology (Williston Park, N.Y.) 1997; 11:25-30
Nabholtz J M, Murawsky M, Alaki M, Aapro M S, Drbal J, Trillet-Lenoir V, Rosso R, Rapoport B, Vandenberg T A, Douma J, Deschênes L, Melnychuk D, Bezwoda W R, Thürlimann Beat, Riva A